Riva Health is a technology company.
Riva Health has raised $16.0M across 1 funding round.
Riva Health has raised $16.0M in total across 1 funding round.
Riva Health is a digital cardiology platform that enables patients to manage hypertension and heart disease using smartphones, AI, and predictive analytics for personalized therapies.[1][2][5] It serves patients and clinicians by turning smartphones into blood pressure monitors via the camera and flash, capturing pulse waveforms processed by signal processing and machine learning algorithms, addressing poor compliance in traditional monitoring.[1][3][5] The company has raised $19.45M total, including a $15M Series A led by Menlo Ventures about a year ago, with strong growth from early ideation to FDA clearance pursuits.[1][3][6]
Riva Health traces its roots to 2013, though some sources note a formal launch or reincorporation around 2020, founded by Dag Kittlaus (co-founder of Siri and CEO) and Tuhin Sinha.[1][2][3] Kittlaus brings AI expertise from Siri to create a smartphone-based health assistant for chronic heart conditions, while Sinha's motivation stems from his father's death from heart disease before age 60, driving development of AI algorithms for better monitoring.[2][3] The idea evolved from Menlo Ventures' Menlo Labs in 2016, where investor Matt Murphy met Sinha; by the Series A, Riva graduated to build a hardware-free solution for blood pressure management, gaining early traction through partnerships and funding.[3]
(Note: A separate entity at rivamedical.com with similar branding focuses on broader preventive care but lacks cardiology specifics; this analysis centers on Riva Health's cardiovascular platform.[4])
Riva Health rides the remote patient monitoring (RPM) wave in digital health, fueled by post-pandemic telehealth adoption, AI advancements in biosensing, and chronic disease burdens like hypertension affecting 1.3 billion globally.[1][3] Timing aligns with smartphone ubiquity and regulatory pushes for FDA-cleared optical sensing (e.g., competitors like Biospectal, Qardio), enabling scalable, equitable care amid clinician shortages and reactive systems.[1][2] Market forces include rising cardiovascular costs ($1T+ annually in the US) and compliance gaps (only 50% adherence), positioning Riva to influence ecosystems via data-driven prevention, potentially integrating with EHRs and expanding AI assistants for chronic care.[3]
Riva Health is poised for launch post-FDA clearance, scaling its smartphone BP program to transform hypertension management into a team-based, proactive model with high compliance potential.[5] Trends like AI wearables convergence, value-based care reimbursements, and global chronic disease growth will accelerate adoption, while partnerships (e.g., Menlo's network) could drive acquisitions or expansions into full cardiology suites.[3] Its influence may evolve from niche RPM innovator to ecosystem leader, simplifying heart health access and redefining prevention—proving smartphones can be vital signs lifelines, much like Siri redefined voice AI.
Riva Health has raised $16.0M in total across 1 funding round.
Riva Health's investors include Abstract Ventures, Alumni Ventures, Andreessen Horowitz, Atomic, DFJ Growth, DST Global, General Catalyst, Khosla Ventures, Menlo Ventures, Quiet Capital, ZhenFund, Eric Ries.
Riva Health has raised $16.0M across 1 funding round. Most recently, it raised $16.0M Seed in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $16.0M Seed | Abstract Ventures, Alumni Ventures, Andreessen Horowitz, Atomic, DFJ Growth, DST Global, General Catalyst, Khosla Ventures, Menlo Ventures, Quiet Capital, ZhenFund, Eric Ries, Jeffrey Lee, Marc Benioff, Othman Laraki |